The first commercial implantation of Mainstay Medical’s ReActiv8 has taken place in Germany.
The implantation was performed by Francis Kilian, orthopaedic and neurosurgeon at the Catholic Hospital Koblenz-Montabaur in Koblenz, Germany.
Kilian comments, “As spine surgeons we are always looking to address the underlying cause of a patient’s condition but until now we had no effective option to offer to patients with chronic low back pain due to impaired control of their back muscles. ReActiv8 represents a significant breakthrough for this large group of patients who are not candidates for spine surgery and fills an important void in our restorative treatment portfolio.”
ReActiv8 works by electrically stimulating the nerves responsible for contracting the key stabilising muscles of the lumbar spine. Activation of these muscles to restore functional spine stability has been shown to facilitate recovery from chronic low back pain.
Mainstay’s European commercial activities for ReActiv8 are initially focused on Germany where the company aims to drive adoption of ReActiv8 in a select number of high volume multi-disciplinary spine care centres, according to a company release.
Mainstay received CE marking for ReActiv8 supported by positive results from the ReActiv8-A clinical trial.
